TY  - JOUR
AU  - Eichhorn, Martin E
AU  - Niedermaier, Benedikt
AU  - Charoentong, Pornpimol
AU  - Klotz, Laura V
AU  - Baum, Philip
AU  - Griffo, Raffaella
AU  - Allgäuer, Michael
AU  - Stenzinger, Albrecht
AU  - Bischoff, Helge
AU  - Schneider, Marc A
AU  - Christopoulos, Petros
AU  - Haberkorn, Uwe
AU  - Heußel, Claus-Peter
AU  - Savai, Rajkumar
AU  - Roberti, Maria Paula
AU  - Zoernig, Inka
AU  - Jäger, Dirk
AU  - Herth, Felix
AU  - Thomas, Michael
AU  - Winter, Hauke
AU  - Eichhorn, Florian
TI  - Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: results of the NEOMUN trial.
JO  - Journal for ImmunoTherapy of Cancer
VL  - 13
IS  - 8
SN  - 2051-1426
CY  - London
PB  - BioMed Central
M1  - DKFZ-2025-01627
SP  - e011874
PY  - 2025
AB  - The phase II NEOMUN trial was conducted to investigate the therapeutic effect of preoperative programmed death receptor-1 inhibitor pembrolizumab for treating non-small cell lung cancer (NSCLC). Herein, we report the final efficacy, safety, and long-term survival results.Patients with resectable stage II/IIIA NSCLC were included. Two cycles of pembrolizumab (200 mg intravenously once every 3 weeks) were administered before surgery. The primary objectives were to assess the feasibility and safety of neoadjuvant treatment and evaluate antitumor activity. We analyzed the clinical parameters and pathologic, radiological, and metabolic tumor response data.29 patients with NSCLC were enrolled. NSCLC histology revealed adenocarcinoma and squamous cell carcinoma in 24 and in 5 patients, respectively. 93.1
KW  - Humans
KW  - Antibodies, Monoclonal, Humanized: therapeutic use
KW  - Antibodies, Monoclonal, Humanized: pharmacology
KW  - Carcinoma, Non-Small-Cell Lung: drug therapy
KW  - Carcinoma, Non-Small-Cell Lung: pathology
KW  - Carcinoma, Non-Small-Cell Lung: mortality
KW  - Male
KW  - Female
KW  - Middle Aged
KW  - Aged
KW  - Lung Neoplasms: drug therapy
KW  - Lung Neoplasms: pathology
KW  - Neoadjuvant Therapy: methods
KW  - Adult
KW  - Programmed Cell Death 1 Receptor: antagonists & inhibitors
KW  - Immunotherapy: methods
KW  - Immune Checkpoint Inhibitors: therapeutic use
KW  - Immune Checkpoint Inhibitors: pharmacology
KW  - Antineoplastic Agents, Immunological: therapeutic use
KW  - Antineoplastic Agents, Immunological: pharmacology
KW  - Biomarker (Other)
KW  - Immune Checkpoint Inhibitor (Other)
KW  - Major pathologic response - MPR (Other)
KW  - Neoadjuvant (Other)
KW  - Non-Small Cell Lung Cancer (Other)
KW  - pembrolizumab (NLM Chemicals)
KW  - Antibodies, Monoclonal, Humanized (NLM Chemicals)
KW  - Programmed Cell Death 1 Receptor (NLM Chemicals)
KW  - Immune Checkpoint Inhibitors (NLM Chemicals)
KW  - Antineoplastic Agents, Immunological (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:40759442
DO  - DOI:10.1136/jitc-2025-011874
UR  - https://inrepo02.dkfz.de/record/303378
ER  -